Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript

SA Transcripts158.67K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST Company Participants Gitanjali Ogawa - VP & Head of Investor RelationsRobert Barrow - CEO & DirectorDaniel Karlin - Chief Medical OfficerMatthew Wiley - Chief Commercial OfficerBrandi Roberts - Chief Financial Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research DivisionBasma Radwan Ibrahim - Leerink Partners LLC, Research DivisionBrian Abrahams - RBC Capital Markets, Research DivisionFrançois Brisebois - LifeSci Capital, LLCPete Stavropoulos - Cantor Fitzgerald & Co., Research DivisionChristopher Chen - Robert W. Baird & Co. Incorporated, Research DivisionArabella NgAmi Fadia - Needham & Company, LLC, Research DivisionSumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good afternoon, and welcome to the Definium Therapeutics Full Year 2025 Financial Results and Business Update Webcast. [Operator Instructions] The webcast is live on the Investor and Media section of the Definium website at definiumtx.com, and a replay will be available after the webcast. I would now like to introduce Gita Jain, Head of Investor Relations of Definium. Please go ahead. Gitanjali OgawaVP & Head of Investor Relations Thank you, operator, and good afternoon, everyone. Thank you for joining us today for a discussion of Definium's full year 2025 financial results and business update. Leading the call today will be Rob Barrow, our Chief Executive Officer, who is joined by Dr. Dan Karlin, our Chief Medical Officer; Brandi Roberts, our Chief Financial Officer; and Matt Wiley, our Chief Commercial Officer. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, our anticipated cash runway and our future expectations, plans, partnerships and